big win

Houston VR training startup wins $90M contract with Air Force, Space Force

HTX Labs will supply immersive training technology and content to the Air Force and its Space Force military partner. Graphic courtesy of HTX Labs

HTX Labs has won a three-year, $90 million contract to provide immersive training capabilities for the Air Force and Space Force.

Under the new contract, which is set to end in September 2026, HTX Labs will supply immersive training technology and content to the Air Force and its Space Force military partner. The Houston company says the contract culminates more than five years of collaboration with the Air Force.

HTX Labs’ EMPACT cloud-based immersive training platform enables instructors and curriculum developers to create immersive lessons within EMPACT’s digital classrooms. HTX Labs says the Air Force and Space Force will retain full ownership of digital assets that are produced and will allow in-house updates of training materials.

EMPACT’s training lessons can be consumed on tablets, laptops, and virtual reality (VR) headsets.

“HTX Labs is honored to have the confidence of the Air Force per this contract that allows us to continue our collaboration with Airmen and Guardians to deliver immersive training capabilities for the warfighter,” Scott Schneider, CEO and head of growth for HTX Labs, says in a news release.

The ties between HTX Labs and the Air Force are strong.

In May, HTX Labs said it had been awarded a Small Business Innovation Research (SBIR) contract for the Tech Training Transformation Cloud project at the Air Force. The project will let airmen access, create, share, and deliver government-owned digital assets, models, simulations, and content for technical training.

Two months later, HTX Labs said retired Air Force Gen. Craig “Pulse” Wills had joined the company as a strategic adviser. During his Air Force tenure, Wills oversaw a makeover of flight training, including the introduction of extended reality (XR) training and adult learning programs.

“HTX Labs was one of the early pioneers of our Pilot Training Next effort, and they’re dedicated to meeting the needs of our warfighters,” says Wills. “Our young military members are the treasure of this nation. We owe them the very best training and tools available to make them lethal, proficient, and prepared to defend this nation and our way of life.”

Founded in 2017, HTX Labs received $3.2 million in royalty-based equity funding last year from Dallas-based Cypress Growth Capital.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted